Trimethoprim-Sulfamethoxazole vs Amoxicillin Ups Hyperkalemia Risk
Trimethoprim-sulfamethoxazole is mostly excreted through the kidneys, and it can cause hyperkalemia by reducing potassium excretion.
Chronic Kidney Disease (CKD)
CHRONIC KIDNEY DISEASE (CKD)
Dapagliflozin Cuts Hospitalization Risk in CKD Population
Among other causes, dapagliflozin treatment reduced the rate of hospitalization due to cancer.
Combination Treatment Beneficial in Albuminuric CKD
7.4 year gain in event-free survival for 50-year-old patients with combo therapy with ACEi/ARB and SGLT2 inhibitors
Recall of Sodium Bicarbonate Injection Due to Vial Breakage Expanded
The recalled product was distributed between October 26, 2021 and August 10, 2022.
Dysnatremias Linked With ESKD, Death
Findings may help clinicians better risk-stratify patients with CKD.
Immunosuppression Ups Infection Risks in Glomerular Disease
Both corticosteroids and nonsteroid immunosuppressive medications were associated with an increased infection risk, investigators found.
RAAS Inhibitor Discontinuation After Hyperkalemia Tied to Adverse Outcomes
Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia.
Apixaban Tied to Lower Risk of Gastrointestinal Bleeding
Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.
Methotrexate Added to Pegloticase for Gout Safe for Kidneys
Investigators report findings from the MIRROR RCT trial, which compared pegloticase plus methotrexate vs placebo for uncontrolled gout.
Kidney Function Declines More Slowly With SGLT2 Inhibitor
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...